The Dulaglutide segment dominated the market with a share of 36.84% in 2025 due to its strong clinical efficacy, convenient once-weekly dosing schedule, proven cardiovascular benefits, and extensive physician adoption across diabetes treatment programs
Citius is encouraged by the constructive engagement with the FDA, Leonard Mazur, the companys chairman and CEO, said in a statement on Friday, adding that Citius plans to complete the remediation activities by the end of 2023 and file a resubmission early in 2024
weight 711.85 g/mol Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 Purity 99.0% Lot number Assigned at shipment Certificate of Analysis Summary CAS 170851-70-4 711.85 g/mol 99% by HPLC from $94 (single) to $115 (10-pack) Selective GHSR-1a agonist pentapeptide
Chavarria L, Alonso J, Garcia-Martinez R, Aymerich FX, Huerga E, Jacas C, et al